PERCEPTIVE INFORMATICS REACHES KEY MILESTONE MARKING 10 MILLION IVRS INTERACTIONS IN SUPPORT OF CLINICAL TRIALS
BOSTON, MA, January 29, 2009 — Perceptive Informatics (Perceptive), the industry’s leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced that it has reached a key milestone, with 10 million calls placed through its ClinPhone Interactive Voice Response System (IVRS) over the past seven years in support of clinical trials for its clients. Perceptive’s IVRS technology manages important clinical trial functions, including patient enrollment and randomization as well as study drug inventory management.
Perceptive’s ClinPhone IVRS typically handles approximately two million interactions per year, depending on study requirements. While the average volume for one study is around 5,000 calls, ClinPhone IVRS has managed over 250,000 calls for larger studies. The IVR system complements the ClinPhone Interactive Web Response System (IWRS) which has a sophisticated web interface for data capture.
“As clinical research experiences rapid growth globally, clients are increasingly turning to Perceptive for our IVR/IWR platforms, which have the infrastructure and scalability needed to support complex global trials,” said Steve Kent, President, Perceptive Informatics. “Marking the 10 millionth call through our IVR system is a significant milestone, which demonstrates the confidence clients have in our ability to deliver robust, secure, and reliable solutions for more efficient trial execution and supply management, as well as support of adaptive trial designs.”
As offered by Perceptive Informatics, the ClinPhone IVR/IWR solutions provide toll-free access and secure web connectivity worldwide and have the ability to manage fluctuating call volumes across multiple large-scale global clinical trials conducted in numerous languages. Due to comprehensive resilience planning, Perceptive’s IVR/IWR capabilities include two data centers that provide 24/7 global support and enable operation of a high number of concurrent trials. The platform is currently managing approximately 600 live clinical trials through 240 phone lines, and has the ability to add additional phone lines as needed. Perceptive’s Randomization and Trial Supply Management (RTSM) technologies, powered by the ClinPhone IVR/IWR platform, provide key features including a broad range of validated randomization methods, automated inventory control, dispensing and titration management, emergency code break capabilities and real-time supply reporting.
The ClinPhone IVR/IWR solution is part of Perceptive’s extensive eClinical product portfolio, which also includes Medical Imaging, Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS) and Electronic Patient Reported Outcomes (ePRO) solutions, as well as eClinical systems integration and implementation services. For more information regarding Perceptive’s IVR/IWR solutions visit: www.perceptive.com.
# # #
About Perceptive Informatics
Perceptive Informatics, a subsidiary of PAREXEL, is the industry’s leading eClinical solutions provider. Perceptive Informatics offers unprecedented access to innovative eClinical technologies and resources, providing clinical trial sponsors, CROs, and other service providers with the benefits of an extensive line of products and services throughout the entire clinical development lifecycle. In August, 2008 Perceptive was joined with ClinPhone plc, and the newly combined organization offers eClinical software and services that increase the efficiency and productivity of clinical research. Perceptive’s expansive product portfolio includes Interactive Voice and Web Response Systems (IVRS/IWRS,) Medical Imaging, Electronic Data Capture (EDC) systems, Clinical Trial Management Systems (CTMS) and Electronic Patient Reported Outcomes (ePRO) solutions, as well as eClinical systems integration and implementation services. For more information about Perceptive Informatics, visit www.perceptive.com.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit www.PAREXEL.com.
This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008 as filed with the SEC on November 7, 2008, which “Risk Factors” discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company’s estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.